Evaluation of Aducanumab for Alzheimer Disease: Scientific Evidence and Regulatory Review Involving Efficacy, Safety, and Futility
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Recent breakthroughs in detecting specific phosphorylated tau fragments in blood, some with apparent high specificity for early AD, open new perspectives.
“Recent breakthroughs with the detection of specific phosphorylated tau fragments in blood, some with apparent high specificity for early AD, are opening new perspectives in this regard 97 .”
From The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics (2022) · cites this paper as [97]
Aducanumab, a monoclonal antibody against Aβ aggregates, obtained FDA approval as an Alzheimer's drug for its ability to reduce the level of Aβ plaques in patients with early AD or MCI.
“Aducanumab, a monoclonal antibody against Aβ aggregates, has obtained the FDA’s approval as an Alzheimer’s drug for its ability to reduce the level of Aβ plaques in patients with early AD or mild cognitive impairment (MCI).46–48”
From Amyloid β-based therapy for Alzheimer’s disease: Challenges, successes and future (2023) · cites this paper as [47]
Two antibody-based drugs, aducanumab and lecanemab, have been approved by the FDA.
“So far, two antibody-based drugs aducanumab and lecanemab have been approved by the FDA”
From Amyloid β-based therapy for Alzheimer’s disease: Challenges, successes and future (2023) · cites this paper as [47]
Aducanumab is the first FDA-approved therapy for Alzheimer's.
“Aducanumab is the first FDA-approved therapy for Alzheimer’s.47,48”
From Amyloid β-based therapy for Alzheimer’s disease: Challenges, successes and future (2023) · cites this paper as [47]
Cites
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059 · see citing works
Andrews, J. S., Desai, U., Kirson, N. Y., Zichlin, M. L., Ball, D. E., & Matthews, B. R. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.06.005 · Cited by 338 · see citing works
Morant, A. V., Jagalski, V., & Vestergaard, H. T. (2019) · Clinical and Translational Science · doi:10.1111/cts.12617 · Cited by 20 · see citing works
Flagged first, then by citations
1 of the 4 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Amyloid β-based therapy for Alzheimer’s disease: Challenges, successes and future
Zhang, Y., Chen, H., Li, R., Sterling, K., & Song, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01484-7 · Cited by 988 · see citing works
“In June 2021, aducanumab was approved by the FDA for medical use.(47,48) However, it is considered controversial due to the lack of sufficient evidence to support its efficacy.”
BackgroundMethodApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies
Raulin, A.-C., Doss, S. V., Trottier, Z. A., Ikezu, T. C., Bu, G., & Liu, C.-C. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00574-4 · Cited by 756 · see citing works
The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics
Karran, E., & De Strooper, B. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00391-w · Cited by 742 · see citing works
Brain-Derived Neurotrophic Factor in Alzheimer’s Disease and Its Pharmaceutical Potential
Gao, L., Zhang, Y., Sterling, K., & Song, W. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00279-0 · Cited by 606 · see citing works
The amyloid cascade hypothesis: an updated critical review
Kepp, K. P., Robakis, N. K. R. K., Høilund‐Carlsen, P. F., Sensi, S. L., & Vissel, B. (2023) · Brain · doi:10.1093/brain/awad159 · Cited by 294 · see citing works
Immunotherapy for Alzheimer’s disease: targeting β-amyloid and beyond
Song, C., Shi, J., Zhang, P., Zhang, Y., Xu, J., Zhao, L., Zhang, R., Wang, H., & Chen, H. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00292-3 · Cited by 266 · see citing works
Cheung, C. Y.-L., Ran, A. R., Wang, S., Chan, V. T. T., Sham, K., Hilal, S., Venketasubramanian, N., Cheng, C., Sabanayagam, C., Tham, Y. C., et al. (2022) · The Lancet Digital Health · doi:10.1016/s2589-7500(22)00169-8 · Cited by 272 · see citing works
Aducanumab produced a clinically meaningful benefit in association with amyloid lowering
Cummings, J., Aisen, P., Lemere, C., Atri, A., Sabbagh, M., & Salloway, S. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00838-z · Cited by 224 · see citing works
Chouliaras, L., Thomas, A., Malpetti, M., Donaghy, P., Kane, J., Mak, E., Savulich, G., Prats-Sedano, M. A., Heslegrave, A. J., Zetterberg, H., et al. (2022) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2021-327788 · Cited by 199 · see citing works
Aducanumab for Alzheimer’s disease?
Walsh, S., Merrick, R. L., Milne, R., & Brayne, C. (2021) · BMJ · doi:10.1136/bmj.n1682 · Cited by 191 · see citing works
Aducanumab: evidence from clinical trial data and controversies
Tampi, R. R., Forester, B. P., & Agronin, M. (2021) · Drugs in Context · doi:10.7573/dic.2021-7-3 · Cited by 190 · see citing works
Role of Aducanumab in the Treatment of Alzheimer’s Disease: Challenges and Opportunities
Vaz, M., Silva, V., Monteiro, C., & Silvestre, S. (2022) · Clinical Interventions in Aging · doi:10.2147/cia.s325026 · Cited by 183 · see citing works
“Thirdly, the close collaboration between the FDA and the sponsor could have impacted the objectivity of the FDA’s decision.(63,64) Furthermore, the AD ́s advocacy groups exerted much pressure on the FDA, defending that a marginal benefit of aducanumab would be significant to patients and caregivers.”
BackgroundNovel Therapeutic Approaches for Alzheimer’s Disease: An Updated Review
Yu, T.-W., Lane, H., & Lin, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158208 · Cited by 182 · see citing works
Withington, C., & Turner, R. S. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.862369 · Cited by 151 · see citing works
Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the US
Ross, E. L., Weinberg, M. S., & Arnold, S. E. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.0315 · Cited by 146 · see citing works
Aducanumab Therapy to Treat Alzheimer’s Disease: A Narrative Review
Beshir, S. A., Aadithsoorya, A. M., Parveen, A., Goh, S. S. L., Hussain, N., & Menon, V. B. (2022) · International Journal of Alzheimer s Disease · doi:10.1155/2022/9343514 · Cited by 119 · see citing works
Can we learn lessons from the FDA's approval of aducanumab?
Liu, K. Y., & Howard, R. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00557-x · Cited by 104 · see citing works
Inflammatory Cascade in Alzheimer’s Disease Pathogenesis: A Review of Experimental Findings
de Oliveira, J., Kucharska, E., Garcez, M. L., Rodrigues, M. S., Quevedo, J., Moreno‐González, I., & Budni, J. (2021) · Cells · doi:10.3390/cells10102581 · Cited by 105 · see citing works
Lacorte, E., Ancidoni, A., Zaccaria, V., Remoli, G., Tariciotti, L., Bellomo, G., Sciancalepore, F., Corbo, M., Lombardo, F. L., Bacigalupo, I., et al. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220046 · Cited by 100 · see citing works
Kumar, N., Kumar, V., Anand, P., Kumar, V. V., Dwivedi, A. R., & Kumar, V. (2022) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2022.116742 · Cited by 81 · see citing works
Amyloid‐β PET in Alzheimer's disease: A systematic review and Bayesian meta‐analysis
Ruan, D., & Sun, L. (2022) · Brain and Behavior · doi:10.1002/brb3.2850 · Cited by 77 · see citing works
Da, Z., Yang, K., Guo, H., Zeng, J., Wang, S., Xu, H., Ge, A., Zeng, L., Chen, S., & Ge, J. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114312 · Cited by 76 · see citing works
Haddad, H. W., Malone, G. W., Comardelle, N. J., Degueure, A. E., Kaye, A. M., & Kaye, A. D. (2022) · Health Psychology Research · doi:10.52965/001c.31925 · Cited by 73 · see citing works
Kellar, D., Register, T. C., Lockhart, S. N., Aisen, P. S. S., Raman, R., Rissman, R. A., Brewer, J. B., & Craft, S. (2022) · Scientific Reports · doi:10.1038/s41598-022-05165-3 · Cited by 72 · see citing works
Yoo, J., Lee, J., Ahn, B., Han, J., & Lim, M. H. (2025) · Chemical Science · doi:10.1039/d4sc06762b · Cited by 74 · see citing works
Aducanumab: a new phase in therapeutic development for Alzheimer’s disease?
Lalli, G., Schott, J. M., Hardy, J., & Strooper, B. D. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202114781 · Cited by 66 · see citing works
Mukhopadhyay, S., & Banerjee, D. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-215065 · Cited by 66 · see citing works
Anderson, T. S., Ayanian, J. Z., Souza, J., & Landon, B. E. (2021) · JAMA · doi:10.1001/jama.2021.15286 · Cited by 66 · see citing works
Aducanumab: The first targeted Alzheimer's therapy
Yang, P., & Sun, F. (2021) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2021.01061 · Cited by 61 · see citing works
Targeting the M1 muscarinic acetylcholine receptor in Alzheimer’s disease
Dwomoh, L., Tejeda, G. S., & Tobin, A. B. (2022) · Neuronal Signaling · doi:10.1042/ns20210004 · Cited by 60 · see citing works
The complement system in neurodegenerative diseases
Nimmo, J., Byrne, R. A. J., Daskoulidou, N., Watkins, L. M., Carpanini, S. M., Zelek, W. M., & Morgan, B. P. (2024) · Clinical Science · doi:10.1042/cs20230513 · Cited by 59 · see citing works
Physiological Roles of Monomeric Amyloid-β and Implications for Alzheimer’s Disease Therapeutics
Jeong, H., Shin, H., Hong, S., & Kim, Y. S. (2022) · Experimental Neurobiology · doi:10.5607/en22004 · Cited by 56 · see citing works
Targeting MicroRNA-485-3p Blocks Alzheimer’s Disease Progression
Koh, H., Lee, S., Lee, H., Min, J.-W., Iwatsubo, T., Teunissen, C. E., Cho, H., & Ryu, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222313136 · Cited by 54 · see citing works
ACU193: An Immunotherapeutic Poised to Test the Amyloid β Oligomer Hypothesis of Alzheimer’s Disease
Krafft, G. A., Jerecı̀ć, J., Siemers, E., & Cline, E. N. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.848215 · Cited by 51 · see citing works
The Anti-Amyloid Monoclonal Antibody Lecanemab: 16 Cautionary Notes
Kepp, K. P., Sensi, S. L., Johnsen, K. B., Barrio, J. R., Høilund‐Carlsen, P. F., Neve, R. L., Alavi, A. A., Herrup, K., Perry, G. L., Robakis, N. K. R. K., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230099 · Cited by 56 · see citing works
Sharma, A., Rudrawar, S., Bharate, S. B., & Jadhav, H. R. (2024) · RSC Medicinal Chemistry · doi:10.1039/d4md00630e · Cited by 52 · see citing works
Alzheimer's and Aducanumab: Unjust Profits and False Hopes
Fleck, L. M. (2021) · The Hastings Center Report · doi:10.1002/hast.1264 · Cited by 50 · see citing works
Shi, M., Chu, F., Zhu, F., & Zhu, J. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-023-03003-5 · Cited by 50 · see citing works
Li, V. O. K., Yang, H., Kaistha, T., Zhang, Q., Downey, J., Gozes, I., & Lam, J. C. K. (2025) · Scientific Reports · doi:10.1038/s41598-025-85947-7 · Cited by 57 · see citing works
Kršek, A., & Batičić, L. (2024) · Future Pharmacology · doi:10.3390/futurepharmacol4020020 · Cited by 49 · see citing works
The Problem of Aducanumab for the Treatment of Alzheimer Disease
Alexander, G. C., & Karlawish, J. (2021) · Annals of Internal Medicine · doi:10.7326/m21-2603 · Cited by 47 · see citing works
Self-citationFronza, M. G., Alves, D. A. C., Praticò, D., & Savegnago, L. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102033 · Cited by 47 · see citing works
Stem cell therapy for Alzheimer’s disease: An overview of experimental models and reality
Qin, C., Wang, K., Zhang, L., & Bai, L. (2022) · Animal Models and Experimental Medicine · doi:10.1002/ame2.12207 · Cited by 45 · see citing works
Microglia-Mediated Neurovascular Unit Dysfunction in Alzheimer’s Disease
Huang, W., Xia, Q., Zheng, F., Zhao, X. L., Ge, F., Xiao, J., Liu, Z., Shen, Y., Ye, K., Wang, D., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221064 · Cited by 46 · see citing works
Age- and sex-specific modifiable risk factor profiles of dementia: evidence from the UK Biobank
Chen, H., Cao, Y., Ma, Y., Xu, W., Zong, G., & Yuan, C. (2023) · European Journal of Epidemiology · doi:10.1007/s10654-022-00952-8 · Cited by 45 · see citing works
Making the Case for Accelerated Withdrawal of Aducanumab
Whitehouse, P. J., Gandy, S., Saini, V., George, D. R., Larson, E. B., Alexander, G. C., Avorn, J., Brownlee, S., Camp, C. J., Chertkow, H. M., et al. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220262 · Cited by 43 · see citing works
Self-citationQin, C., Bai, L., Li, Y., & Wang, K. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-02765-8 · Cited by 42 · see citing works
Potential of Sorghum Polyphenols to Prevent and Treat Alzheimer’s Disease: A Review Article
Rezaee, N., Fernando, W. M. A. D. B., Hone, E., Sohrabi, H. R., Johnson, S. K., Gunzburg, S. T., & Martins, R. N. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.729949 · Cited by 42 · see citing works
Sarazin, M., Lagarde, J., Haddad, I., de Souza, L. C., Bellier, B., Potier, M., Bottlaender, M., & Dorothée, G. (2024) · Nature Aging · doi:10.1038/s43587-024-00630-2 · Cited by 40 · see citing works
Amyloid-β and α-Synuclein Immunotherapy: From Experimental Studies to Clinical Trials
Nimmo, J., Kelly, L., Verma, A. K., Carare, R. O., Nicoll, J. A. R., & Dodart, J. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.733857 · Cited by 40 · see citing works
Bajaj, S., Jain, S., Vyas, P., Bawa, S., & Vohora, D. (2021) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2021.06.022 · Cited by 39 · see citing works
Gao, Y., Liu, J., Wang, J., Liu, Y., Zeng, L., Ge, W., & Ma, C. (2022) · Brain Pathology · doi:10.1111/bpa.13047 · Cited by 35 · see citing works
Dendrimers and Derivatives as Multifunctional Nanotherapeutics for Alzheimer’s Disease
Moreira, D. A., Santos, S. D., Leiro, V., & Pêgo, A. P. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041054 · Cited by 39 · see citing works
“Real world” eligibility for aducanumab
Canevelli, M., Rossi, P. D., Astrone, P., Consorti, E., Vanacore, N., & Cesari, M. (2021) · Journal of the American Geriatrics Society · doi:10.1111/jgs.17390 · Cited by 36 · see citing works
A Review of the Current Status of Disease-Modifying Therapies and Prevention of Alzheimer’s Disease
Parums, D. V. (2024) · Medical Science Monitor · doi:10.12659/msm.945091 · Cited by 36 · see citing works
Xing, X., Zhang, X., Wang, K., Wang, Z., Feng, Y., Li, X., Hua, Y., Zhang, L., & Dong, X. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01669-4 · Cited by 36 · see citing works
Lipid metabolism transcriptomics of murine microglia in Alzheimer’s disease and neuroinflammation
Shippy, D. C., & Ulland, T. K. (2023) · Scientific Reports · doi:10.1038/s41598-023-41897-6 · Cited by 35 · see citing works
Targeting sialylation to treat central nervous system diseases
Lünemann, J. D., von Gunten, S., & Neumann, H. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.09.002 · Cited by 35 · see citing works
Lessons from antiamyloid-β immunotherapies in Alzheimer's disease
Plascencia‐Villa, G., & Perry, G. L. (2023) · Handbook of clinical neurology · doi:10.1016/b978-0-323-85555-6.00019-9 · Cited by 34 · see citing works
Raising the bar for using surrogate endpoints in drug regulation and health technology assessment
Dawoud, D., Naci, H., Ciani, O., & Bujkiewicz, S. (2021) · BMJ · doi:10.1136/bmj.n2191 · Cited by 34 · see citing works
Haddad, H. W., Malone, G. W., Comardelle, N. J., Degueure, A. E., Poliwoda, S., Kaye, R. J., Murnane, K. S., Kaye, A. M., & Kaye, A. D. (2022) · Health Psychology Research · doi:10.52965/001c.37023 · Cited by 33 · see citing works
The 2021 yearbook of Neurorestoratology
Sharma, H. S., Chopp, M., Chen, L., Sarnowska, A., Xue, M., Ao, Q., Siniscalco, D., Chen, L., Hawamdeh, Z. M., & Huang, H. (2022) · Journal of Neurorestoratology · doi:10.1016/j.jnrt.2022.100008 · Cited by 31 · see citing works
Wei, H., Masurkar, A. V., & Razavian, N. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1149036 · Cited by 30 · see citing works
Vascular endothelial‐cadherin as a marker of endothelial injury in preclinical Alzheimer disease
Tarawneh, R. M., Kasper, R. S., Sanford, J., Phuah, C., Hassenstab, J. J., & Cruchaga, C. (2022) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51685 · Cited by 29 · see citing works
Nanoparticles-based anti-aging treatment of Alzheimer’s disease
Chu, J., Ji, W., Zhuang, J., Gong, B., Chen, X., Cheng, W., Liang, W., Li, G., Gao, J., & Yin, Y. (2022) · Drug Delivery · doi:10.1080/10717544.2022.2094501 · Cited by 29 · see citing works
Yeo-Teh, N. S. L., & Tang, B. L. (2023) · Science and Engineering Ethics · doi:10.1007/s11948-022-00422-0 · Cited by 28 · see citing works
Alfei, S., & Zuccari, G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020844 · Cited by 28 · see citing works
Panza, F., Dibello, V., Sardone, R., Zupo, R., Castellana, F., Leccisotti, I., Moretti, M. C., Altamura, M., Bellomo, A., Daniele, A., et al. (2025) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2025.2463963 · Cited by 27 · see citing works
D’Andrea, C., Cazzaniga, F. A., Bistaffa, E., Barucci, A., de Angelis, M., Banchelli, M., Farnesi, E., Polykretis, P., Marzi, C., Indaco, A., et al. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00367-9 · Cited by 27 · see citing works
Approved drugs and natural products at clinical stages for treating Alzheimer’s disease
Ma, Y., Liu, S., Zhou, Q., Zhong-hua, L., ZHANG, Z., & Yu, B. (2024) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(24)60606-0 · Cited by 26 · see citing works
Aducanumab: A new hope in Alzheimer's disease
Ali, R., Gupta, G. D., & Chawla, P. A. (2022) · Health Sciences Review · doi:10.1016/j.hsr.2022.100039 · Cited by 26 · see citing works
Aducanumab in Alzheimer’s Disease: A Critical Update
Ashique, S., Sirohi, E., Kumar, S., Rihan, M., Mishra, N., Bhatt, S., Gautam, R. K., Singh, S. K., Gupta, G., Chellappan, D. K., et al. (2023) · Current Medicinal Chemistry · doi:10.2174/0929867331666230727103553 · Cited by 26 · see citing works
Tian, L., Long, G., Zhu, S., Wang, Y., Xu, P., Liu, L., Yao, H., Fang, S., Chen, S., & Li, S. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2427257122 · Cited by 29 · see citing works
Delbreil, P., Rabanel, J., Banquy, X., & Brambilla, D. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114397 · Cited by 25 · see citing works
Making the Case for the Accelerated Withdrawal of Aducanumab
Whitehouse, P. J., & Saini, V. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220264 · Cited by 23 · see citing works
Can We Treat Neurodegenerative Proteinopathies by Enhancing Protein Degradation?
Engelender, S., Stefanis, L., Oddo, S., & Bellucci, A. (2022) · Movement Disorders · doi:10.1002/mds.29058 · Cited by 23 · see citing works
Nanomodulators That Target Alzheimer’s Disease: A Review
Pradhan, N., & Jana, N. R. (2024) · ACS Applied Nano Materials · doi:10.1021/acsanm.3c04846 · Cited by 22 · see citing works
Prion protein and prion disease at a glance
Zhu, C., & Aguzzi, A. (2021) · Journal of Cell Science · doi:10.1242/jcs.245605 · Cited by 22 · see citing works
Togher, Z., Dolphin, H., Russell, C., Ryan, M., Kennelly, S., & O’Dowd, S. (2022) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.5789 · Cited by 22 · see citing works
Zelek, W. M., Bevan, R. J., Nimmo, J., Dewilde, M., Strooper, B. D., & Morgan, B. P. (2024) · Brain · doi:10.1093/brain/awae278 · Cited by 22 · see citing works
Zinc utilization by microglia in Alzheimer’s disease
Shippy, D. C., Oliai, S. F., & Ulland, T. K. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107306 · Cited by 23 · see citing works
Kotarba, S., Kozłowska, M., Scios, M., Saramowicz, K., Barczuk, J., Granek, Z., Siwecka, N., Wiese, W., Golberg, M., Galita, G., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910797 · Cited by 21 · see citing works
TAR DNA‐binding protein 43 oligomers in physiology and pathology
Lye, Y. S., & Chen, Y. (2022) · IUBMB Life · doi:10.1002/iub.2603 · Cited by 21 · see citing works
Lian, Y., Jia, Y., Wong, J., Zhou, X., Song, W., Guo, J., Masters, C. L., & Wang, Y. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02324-4 · Cited by 21 · see citing works
Retinal thickness predicts the risk of cognitive decline over five years
Eppenberger, L. S., Li, C., Wong, D. W. K., Tan, B., Garhöfer, G., Hilal, S., Chong, E. J. Y., Toh, A. Q., Venketasubramanian, N., Chen, C., et al. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01627-0 · Cited by 19 · see citing works
Frustrated peptide chains at the fibril tip control the kinetics of growth of amyloid-β fibrils
Xu, Y., Knapp, K., Le, K. N., Schafer, N. P., Safari, M. S., Davtyan, A., Wolynes, P. G., & Vekilov, P. G. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2110995118 · Cited by 19 · see citing works
Accelerated Approval of Aducanumab: Where Do We Stand Now?
Levy, H. B. (2021) · Annals of Pharmacotherapy · doi:10.1177/10600280211050405 · Cited by 19 · see citing works
Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease in the Era of Disease-Modifying Treatments
Paraskevas, G. P., & Kapaki, E. N. (2021) · Brain Sciences · doi:10.3390/brainsci11101258 · Cited by 18 · see citing works
Luo, J. J., Wallace, W., & Kusiak, J. W. (2022) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2022.120294 · Cited by 17 · see citing works
Elsheikh, S., Coles, N. P., Achadu, O. J., Filippou, P. S., & Khundakar, A. A. (2024) · Biosensors · doi:10.3390/bios14010033 · Cited by 18 · see citing works
The oxidatively damaged DNA and amyloid-β oligomer hypothesis of Alzheimer's disease
Sanders, O. D., Rajagopal, L., & Rajagopal, J. A. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.08.019 · Cited by 18 · see citing works
Cohen, D. E., Kim, H., Levine, A., Devanand, D. P., Lee, S., & Goldberg, T. E. (2023) · International Psychogeriatrics · doi:10.1017/s1041610223000911 · Cited by 17 · see citing works
Chua, J., Li, C., Antochi, F. A., Toma, E., Wong, D. W. K., Tan, B., Garhöfer, G., Hilal, S., Popa‐Cherecheanu, A., Chen, C., et al. (2025) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70041 · Cited by 20 · see citing works
Bajaj, S., Zameer, S., Jain, S., Yadav, V., & Vohora, D. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00699 · Cited by 17 · see citing works
Wang, C. S., Chang, W. H., Yang, Y. K., & Cheng, K. (2023) · Journal of Medical and Biological Engineering · doi:10.1007/s40846-023-00810-2 · Cited by 16 · see citing works
Pharmacogenomics of Dementia: Personalizing the Treatment of Cognitive and Neuropsychiatric Symptoms
Vuić, B., Milos, T., Tudor, L., Perković, M. N., Konjevod, M., Erjavec, G. N., Farkaš, V., Uzun, S., Mimica, N., & Štrac, D. Š. (2023) · Genes · doi:10.3390/genes14112048 · Cited by 17 · see citing works
Parums, D. V. (2021) · PubMed Central · doi:10.12659/msm.934077 · Cited by 16 · see citing works
Light-based gamma entrainment with novel invisible spectral flicker stimuli
Hansen, L. S., Carstensen, M. S., Henney, M. A., Nguyen, N. M., Thorning‐Schmidt, M. W., Broeng, J., Petersen, P. M., & Andersen, T. (2024) · Scientific Reports · doi:10.1038/s41598-024-75448-4 · Cited by 17 · see citing works
Sadleir, K. R., Gómez, K., Edwards, A. E., Patel, A. J., Ley, M. L., Khatri, A. W., Guo, J., Mahesh, S., Watkins, E. A., Popović, J., et al. (2025) · Acta Neuropathologica · doi:10.1007/s00401-025-02888-1 · Cited by 15 · see citing works
Schmid, J. C., Frey, K., Scheiner, M., Garzón, J. F. G., Stafforst, L., Fricke, J., Schuppe, M., Schiewe, H., Zeeck, A., Weber, T., et al. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202106802 · Cited by 15 · see citing works
- Authors
- Alexander, G. C., Emerson, S., & Kesselheim, A. S.
- Affiliations
- Johns Hopkins University (US)
- University of Washington (US)
- Brigham and Women's Hospital (US)
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2021-05-04
- Volume
- 325
- Issue
- 17
- Pages
- 1717
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W3149600507
- Cited by
- 240
- References
- 4
- Citations by year
- 2026: 25 · 2025: 24 · 2024: 41 · 2023: 37 · 2022: 59 · 2021: 54
- FWCI
- 30.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- aducanumab, Alzheimer's disease, amyloid-beta, anti-amyloid therapy, drug efficacy, clinical trials
- MeSH terms
- Alzheimer Disease, Humans, United States, United States Food and Drug Administration, Randomized Controlled Trials as Topic, Treatment Failure, Drug Approval, Medical Futility, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
